Instrument Inactif

Autres langues Arch Therapeutics Inc OTC Bulletin Board

Actions

Equipement, fournitures et distribution médicale

Autres langues

31/12	Arch Therapeutics, Inc. Went Out of Business
10/12	Modified Second Amended Liquidation Plan Approved for Arch Therapeutics, Inc.
09/09/25	Second Amended Liquidation Plan and Disclosure Statement Filed by Arch Therapeutics, Inc.
27/08/25	First Amended Liquidation Plan and Disclosure Statement Filed by Arch Therapeutics, Inc.
10/07/25	Amended Disclosure Statement Filed by Arch Therapeutics, Inc.
10/07/25	Liquidation Plan and Disclosure Statement Filed by Arch Therapeutics, Inc.
25/06/25	Motion for Asset Sale Approved for Arch Therapeutics, Inc.
27/05/25	Final DIP Financing Approved for Arch Therapeutics, Inc.
27/05/25	Notice of Intent to Sale Filed by Arch Therapeutics, Inc.
27/05/25	Bidding Procedure Approved for Arch Therapeutics, Inc.
15/05/25	Motion for Asset Sale Filed by Arch Therapeutics, Inc.
02/05/25	Interim DIP Financing Approved for Arch Therapeutics, Inc.
21/04/25	Motion for Joint Administration Approved for Arch Therapeutics, Inc.
18/04/25	Motion for Joint Administration Filed by Arch Therapeutics, Inc.
18/04/25	Arch Therapeutics, Inc. Filed for Bankruptcy
07/02/25	Arch Therapeutics, Inc. Announces Resignation of Michael S. Abrams from CFO
07/02/25	Arch Therapeutics, Inc. Appoints Terrence W. Norchi, to the Roles of Principal Accounting Officer
08/11/24	Arch Therapeutics : Material Agreement Form 8 K
01/10/24	Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
10/09/24	Arch Therapeutics, Inc. announces tranche update
30/08/24	Arch Therapeutics, Inc. Announces Resignation of Laurence Hicks as Board Member
19/08/24	Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024
16/08/24	Arch Therapeutics, Inc. Announces Resignation of Punit Dhillon as Board Member
29/07/24	Arch Therapeutics, Inc. announces tranche update
30/06/24	Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC